Login / Signup

Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis: Incidence, Risk Factors, and Effect of Antiviral Prophylaxis.

Camille GarnierDavid RibesDominique ChauveauAntoine HuartGrégory PugnetDaniel AdoueGrégoire PrevotLaurent AlricPierre DelobelHélène DerumeauxCatherine MengelleLaurent SaillerGuillaume Moulis
Published in: The Journal of rheumatology (2018)
The incidence of zoster is high in systemic vasculitis and in patients with SLE exposed to intravenous CYC. CYC may favor postherpetic neuralgia. Prophylaxis by VCV should be considered, particularly in cases of lymphopenia < 500/µl at CYC initiation and during the year after.
Keyphrases
  • risk factors
  • systemic lupus erythematosus
  • disease activity
  • high dose
  • low dose
  • rheumatoid arthritis
  • drug induced